Australia · Delayed Price · Currency is AUD Opthea Company Description
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.
The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases.
The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Country | Australia |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jeremy Levin |
Contact Details
Address: Level 9 Melbourne, VIC VIC Australia | |
| Phone | 61 3 9826 0399 |
Stock Details
| Ticker Symbol | OPT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000OPT2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Chief Executive Officer and Chairperson |
| Hamish George | Chief Financial Officer and Joint Company Secretary |
| Dr. Stuart Mudge | Chief Operating Officer |
| Dr. Michael Gerometta Ph.D. | Chief Technology Officer |
| Stephanie Vipond | Joint Company Secretary |